Original, source-linked analysis with study design, model boundaries and limitations kept visible. Research findings are not device-wide promises.
For professional education and institutional evaluation. Published research is not authorization for use in Mexico or another country. Confirm the exact device, local registration, current instructions and institutional permissions before clinical use.
Source-based editorial analysis by OMNIBOT MX. No independent medical reviewer is asserted. Read the original publication and assess applicability with your institution.
This trial offers randomized, procedure-specific feasibility evidence. Completion without conversion in this selected sample is not a system-wide success rate. Early comparisons cannot establish durable oncological or functional equivalence, and the precision of the success estimate matters as much as the absence of a statistically significant difference.
Shaoxi Niu, Liyan Ao · European Urology Open Science; 64:2–8
42 patients; 21 per randomized group.
Small sample; three-month follow-up. The success-rate difference interval (−15.46% to +15.46%) does not establish conclusive equivalence at a 10% margin.
The randomized design and defined composite make this useful for a short-term technical-success evaluation. Noninferiority is specific to the chosen endpoint and margin; it is not a declaration that all outcomes or all settings are equivalent. Hospitals should examine case selection and operator experience before applying these findings.
Yu Gao, Yang Yang · International Journal of Surgery; 110(5):2803–2809
62 patients across four centers; 31 per group.
Small sample, highly experienced surgeons and short follow-up. Three-month assessment cannot establish long-term cancer control.
This is comparative nonrandomized evidence, not a randomized effectiveness trial. The 59-patient MP1000 subgroup must be distinguished from the overall cohort. Patient selection, platform assignment and operator experience may influence the apparent similarity of short-term outcomes.
Pengyu Guo, Honglei Wang · World Journal of Urology; 43(1):205
261 patients in three platform groups; 59 in the EDGE MP1000 group.
Nonrandom allocation, single center and multiple procedure/platform subgroups. Verification covers metadata and abstract, not complete methods.
This record must stay visibly mixed-model. It supports feasibility of the combined cohort but cannot estimate independent MP1000 performance. Without a comparator and model-stratified outcomes, safety and economic claims should remain narrow.
Yiming Zhang, Peng Xu · Journal of Robotic Surgery; 20:202
129 patients in a combined MP1000/MP2000 retrospective cohort.
Retrospective, uncontrolled high-volume center; verified abstract does not provide model-stratified results. Reported costs do not prove comparative cost-effectiveness.